Health and genetic ancestry testing: time to bridge the gap by Andrew Smart et al.
DEBATE Open Access
Health and genetic ancestry testing: time
to bridge the gap
Andrew Smart1* , Deborah A. Bolnick2 and Richard Tutton3
Abstract
Background: It is becoming increasingly difficult to keep information about genetic ancestry separate from information
about health, and consumers of genetic ancestry tests are becoming more aware of the potential health risks associated
with particular ancestral lineages. Because some of the proposed associations have received little attention from oversight
agencies and professional genetic associations, scientific developments are currently outpacing governance regimes for
consumer genetic testing.
Main text: We highlight the recent and unremarked upon emergence of biomedical studies linking markers of genetic
ancestry to disease risks, and show that this body of scientific research is becoming part of public discourse connecting
ancestry and health. For instance, data on genome-wide ancestry informative markers are being used to assess health
risks, and we document over 100 biomedical research articles that propose associations between mitochondrial
DNA and Y chromosome markers of genetic ancestry and a wide variety of disease risks. Taking as an example an
association between coronary heart disease and British men belonging to Y chromosome haplogroup I, we show
how this science was translated into mainstream and online media, and how it circulates among consumers of
genetic tests for ancestry. We find wide variations in how the science is interpreted, which suggests the potential
for confusion or misunderstanding.
Conclusion: We recommend that stakeholders involved in creating and using estimates of genetic ancestry
reconsider their policies for communicating with each other and with the public about the health implications
of ancestry information.
Keywords: Direct-to-consumer genetic tests, Genetic ancestry, Disease/Health risk, Regulation, Social implications,
Public understanding
Background
While genetic ancestry tests marketed to consumers do
not currently claim to provide information about disease
risk, it is becoming increasingly difficult to keep infor-
mation about ancestry separate from information about
health. In this article, we consider the recent and unre-
marked upon growth in genetic tests and biomedical
studies linking markers of genetic ancestry to various
diseases and medical conditions. These developments
are becoming part of public discourse connecting ancestry
and health, but because genetic testing companies, over-
sight agencies, and professional genetic associations
have largely treated health and ancestry genetic tests as
independent and distinct, little guidance is available to
help consumers understand and interpret the reported
connections between genetic ancestry and disease risk.
Consequently, when such findings circulate in the pub-
lic realm, consumers learn that there may be health
risks tied to their genetic ancestry even though com-
panies do not report those associations. There is there-
fore potential for confusion or misunderstanding that is
problematic for both consumers and the scientific com-
munity. We argue that the various stakeholders in genetic
ancestry testing need to reconsider what they communi-
cate about the health implications of ancestry information,
both to the public and to each other, in order to effectively
bridge the gap that currently exists in policies and
consumer guidance regarding genetic tests for ancestry
and health.
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The gap between genetic tests for health and
ancestry
Genetic ancestry tests were first marketed directly to
consumers in 2000, for the purpose of reconstructing
genealogies and investigating personal genetic heritage.
They quickly became the most popular of all consumer
genetic testing services, and more than three million in-
dividuals have reportedly purchased these tests to date
[1, 2]. Over the last 15 years, companies [3], regulators
[4] and professional scientific associations [5, 6] have
treated ancestry genetic tests differently than medical or
health-oriented genetic tests. Tests that make health-
related claims or have implications for the prevention,
diagnosis, or treatment of disease have been subject to
greater scrutiny and oversight, as regulators have sought
to ensure that potentially life-changing healthcare deci-
sions are not made on the basis of poor quality informa-
tion or with a lack of appropriate medical knowledge,
advice, and support [7]. Genetic ancestry tests have re-
ceived less attention from legislators, policy makers and
regulatory agencies because they are not marketed expli-
citly for disease diagnosis, treatment, or prevention, and
have thus been seen as more “recreational”, less conse-
quential, and less ethically problematic. This differenti-
ation between ancestry and health genetic testing has
seemed appropriate because the two types of tests have
had such different applications.
However, recent developments demonstrate that the
boundary between ancestry-related and health-related
genetic testing is more porous than previously suggested
[8], and it is being transgressed in a variety of ways.
When genetic testing company 23andMe suspended its
‘health reports’ in 2013, following a warning from the
US Food and Drug Administration (FDA), it continued
to provide customers with ancestry information and
their raw genetic data [9, 10]. With these ancestry testing
data, consumers could still obtain an assessment of their
health risks using independent online ‘interpretation-only’
services for as little as $5 [11]. More explicit links between
genetic ancestry and health are evident in 23andMe’s re-
launched Health + Ancestry Service, which was approved
by the FDA as a ‘medical device’ and provides both ances-
try and health information. This service directly connects
ancestry to health in its ‘wellness’ reports for traits like lac-
tose intolerance and in its ‘carrier status’ reports for med-
ical conditions like cystic fibrosis and sickle cell
anemia, as both link risk estimates to named racial/
ethnic groups. At least one other leading genetic test-
ing company (Ancestry.com) is in discussions with the
FDA about expanding its service to include similar car-
rier status reports [12]. Furthermore, as we show in
this article, even when genetic ancestry tests report
only an individual’s ancestry, consumers can become
aware of possible health risks tied to their genetic
ancestry via media coverage of scientific studies and
online discussion groups.
This blurring of the line between genetic ancestry and
health accentuates the gaps that currently exist in policy
and in the available guidance for consumers because little
attention has been given to the health implications of
genetic ancestry testing. However, as others have noted, it
may become common for consumers to share their ances-
try test results or ancestry-related estimates of disease risk
with their physicians, expecting such information to in-
form their healthcare decisions and improve their quality
of care [13, 14]. It is therefore crucial that we bridge these
gaps to ensure that genetic testing information is used ap-
propriately in health-related decisions and clinical care.
This is especially important because most physicians lack
the expertise needed to interpret and contextualize the re-
sults of genetic tests: only 29% of US clinicians surveyed
rate their knowledge of genetics as excellent, very good, or
good [15], and less than a third of the physicians surveyed
in five European countries were confident or very
confident in their ability to carry out basic medical genetic
tasks [16]. Given these findings, there is a real risk that
consumers or their physicians could make problematic
and potentially irreversible healthcare decisions based on
inaccurate, misleading, or misinterpreted genetic testing
results. Genetic ancestry information has been misinter-
preted or over-interpreted in the past [17–19], and it has
been used in ways that reach far beyond the intended or
anticipated scientific applications — for example, in con-
troversial attempts to use genetic ancestry tests to support
Native American tribal membership claims [20] and to
infer nationality in asylum cases [21].
Thus, it is critical that we recognize and address the
increasingly porous boundary between genetic tests for
ancestry and health because (1) genetic ancestry tests can
provide information that has consequences for health
decision-making, (2) test-takers may have unrealistic
expectations about the scientific and medical certainties
offered by the tests they have purchased, (3) many physi-
cians are not prepared to interpret and apply the genetic
test results that their patients may bring into the clinic,
and (4) better guidance for consumers is needed to ensure
that health-related information from genetic ancestry tests
is interpreted and applied in valid ways. This is especially
important because, as we show in the next section, scien-
tific and biomedical studies have been drawing ever more
connections between ancestry and health, and there is evi-
dence that these connections are beginning to affect con-
sumer interpretations of their genetic ancestry test results.
Mounting evidence of connections between
genetic ancestry and disease risk
Genetic ancestry plays an important role in contemporary
biomedical science. Medical genetic studies, for instance,
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commonly use ancestry inferences derived from auto-
somal markers (typically single nucleotide polymorphisms
or “ancestry informative markers”) to control for popula-
tion stratification, a practice that underpins the now rou-
tine reporting of population-specific or ancestry-specific
estimates of disease risks and drug response in genetic
epidemiology [13, 22]. Far less attention has been given to
the fact that studies using uniparental genetic markers
have uncovered connections between ancestry and health.
These tests have been a mainstay of the direct-to-consumer
ancestry-testing marketplace, but have been widely con-
sidered to have little biomedical value [13].
Over the last decade, hundreds of biomedical studies
have been published that suggest that certain mito-
chondrial DNA (mtDNA) and Y chromosome variants
(and the haplogroups defined by those variants) are
associated with an increased risk of disease and other
health complications [23]. These variants and hap-
logroups have been linked to a diverse array of common
diseases and medical conditions, including coronary artery
disease, myocardial infarction, ischaemic stroke, heart
transplant complications, Leber hereditary optic neuro-
pathy, advanced age-related macular degeneration,
hearing loss, osteoarthritis, osteoporosis, multiple scler-
osis, Alzheimer’s and Parkinson’s disease, complications
from type 2 diabetes (especially retinopathy, neuro-
pathy, nephropathy, and renal failure), several types of
cancer (breast, thyroid, pancreatic, esophageal, colorec-
tal, prostate, renal, and lung cancer), and the rate of
AIDS progression in HIV patients (an additional table
shows examples of associations discussed in the bio-
medical literature [see Additional file 1]). The exact
causes of these associations are not always clear, but it
is thought that the associated genetic variants alter the
expression of key gene pathways [24] or, in the case of
mtDNA, contribute to the development and progression
of disease by affecting energy metabolism and important
cellular processes, including ATP synthesis, reactive oxy-
gen species (ROS) production, oxygen consumption effi-
ciency, calcium signaling, and apoptosis [25–27].
It is important to note that the quality of studies
reporting associations between mtDNA/Y chromosome
haplogroups and disease susceptibility is quite variable.
Some haplogroup-disease associations are supported by
multiple independent studies with rigorous statistical
designs, but many others are not. The biomedical litera-
ture includes a large number of studies that suffer from
small sample sizes, inappropriate controls for population
stratification, and/or problematic statistics (for example,
P-values that have not been corrected for multiple com-
parisons), so some of the reported haplogroup-disease
associations are almost certainly false positives. Other
researchers have also drawn attention to these problems
[23, 28]. However, regardless of the quality of these
studies, many publications present possible associations
between mtDNA/Y haplogroups and disease risk, and
consumers are becoming aware of these reports as they
garner media attention and enter public discourse.
In 2012, for example, a study published in The Lancet
found that British men belonging to Y chromosome
haplogroup I have a 50% higher age-adjusted risk of
coronary artery disease (CAD) than other British men,
with haplogroup I being the most significant predictor
of CAD after HDL cholesterol and lipid-lowering treat-
ment [24]. This finding was widely reported by the
media in the UK, US, and Australia, under headlines
about heart disease risk being inherited along paternal
lines (Tables 1 and 2). This coverage demonstrated the
potential for raised consumer expectations about the
value of genetic ancestry information to health, and the
future possibilities of acting on that information. One
article, for example, suggested that: “when a screening test
is developed to find those Y chromosome gene clusters
and researchers have a better understanding of how they
act, it may be possible to protect some [unlucky men]
from having heart attacks.” [29] The UK National Health
Service added an extensive discussion of ancestral hap-
logroups and CAD to their patient information website,
NHS Choices, after the study was published — albeit to
argue that this information was not of immediate use for
tackling CAD in the UK because, among other reasons,
“men are unlikely to know their specific haplogroup, so
are unlikely to know whether they may be at increased
risk of CAD” [30]. Ancestry testing consumers dis-
cussed this Lancet study (along with other reports of
haplogroup-associated disease susceptibilities) in online
forums (in threads entitled, for example, “Medical con-
ditions associated with Y-chromosome haplogroups”
and “Do not read if you are a hypochondriac…”), and a
Principal Scientist at 23andMe blogged about the study,
expressing skepticism about the study’s conclusions and
offering an alternative analysis using his company’s data
(Table 3). Thus, by following the circulation of this
study in public domains, we can see variation in how
the study was understood, disagreement over the ro-
bustness of its conclusions, and a lack of clarity about
the significance of genetic ancestry markers like hap-
logroups to health.
While similar observations can be made about studies
of autosomal or genome-wide markers and disease risk,
we have focused here on uniparental genetic markers be-
cause mtDNA and Y chromosome tests are the two
types of genetic ancestry tests that companies, policy-
makers, regulators, and professional scientific associa-
tions have invariably treated as less relevant to health.
However, as we have shown, there is public interest in
the extensive biomedical literature investigating the as-
sociations between mtDNA/Y chromosome haplogroups
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and disease, and some consumers of genetic ancestry
tests are already trying to understand how their an-
cestry is relevant to their health and disease prognosis
in light of these research findings. Other consumers
are also likely to encounter the results of these bio-
medical studies in the popular press, in online for-
ums, in literature from their healthcare provider, or
in well-known medical journals, and they too may
grapple with the possible health implications of their
genetic ancestry test results. Therefore, even when
genetic ancestry tests report only an individual’s an-
cestral lineage or uniparental haplogroup, consumers
can become aware of the possible relationship with
genetic health risks because scientists have linked
haplogroup ancestry to health outcomes.
Conclusions
Like the repurposing of genome-wide ancestry test data
to assess health risks, and like the use of autosomal
genetic markers in genetic epidemiology to identify
population-specific disease risks and drug response, the
reported associations between uniparentally-inherited
haplogroups and various diseases represent another
blurring of the line between genetic information on
health and ancestry. Developments in scientific know-
ledge and commercial practice appear to be outpacing
the current oversight and governance regimes that
largely treat genetic tests for ancestry and health as sep-
arate and distinct.
We therefore suggest that it is time for the various
stakeholders in genetic ancestry testing to reconsider
what they communicate about the health implications of
ancestry information, both to the public and to each
other. This will require considering some difficult ques-
tions. For example, can and should consumer genetic
testing companies take responsibility for the ways in
which test-takers connect ancestry test results with other
publicly available information? Can and should genetic
testing companies, alongside scientific associations and
consumer advocates, provide guidance to consumers
about the accuracy and reliability of the various postu-
lated associations between haplogroups (or other genetic
markers) and health risks? How can those who commu-
nicate about the relevant science (scientific researchers,
journal editors, science journalists, genetic testing
companies, consumer advocates, policy advisors, etc.)
achieve maximum clarity regarding the potential health
implications of genetic ancestry (or the lack of them),
and make effective use of the published critiques of the
putative links between uniparental haplogroups and
health risks [23, 28]? Should there be any changes to
policies governing the regulation or oversight of con-
sumer genetic testing, or additions to guidelines being
developed by professional associations like the American
Society of Human Genetics (ASHG)?
To help address the issues raised here, we make five
recommendations for stakeholders in consumer genetic
testing to consider:
(1) The ASHG or another respected professional
genetics society should organize a roundtable
to bring the various stakeholders together to
produce authoritative guidance that will inform
and benefit consumers, and help create a set of
standards for the industry to follow. This guidance
should make clear what we can and cannot
know from genetic ancestry testing, and provide
guidance regarding the accuracy and reliability of
associations between genetic markers and health
risks. Industry representatives, consumer advocates,
policy and legal advisors, biomedical researchers,
social scientists, and regulators should all be
involved in drafting this guidance.
(2) Consumer advocates, scientific organizations,
companies, science journalists, and government
agencies should play a role in making this
information available to consumers.
(3)Genetic ancestry testing companies should
report only associations between genetic
markers and diseases/medical conditions that
have been scientifically validated. They should
also provide information about the limitations of
their tests (as 23andMe now does as part of their
‘carrier status’ and ‘wellness’ reports; [31]) and
include information about how to interpret the
connections between ancestry and health among
their FAQs.
(4)Medical schools and continuing medical education
(CME) programs should discuss the potential health
implications of genetic ancestry information so that
physicians can help their patients to interpret and
contextualize their genetic testing results.
(5) Policy-makers and government agencies may
wish to reconsider current oversight regimes for
direct-to-consumer genetic testing in light of the
increasingly porous boundaries between tests for
health and ancestry.
Our recommendations are aimed at encouraging
novel and timely interventions into ongoing debates
about direct-to-consumer genetic tests, especially
since the US FDA, European Commission, ASHG, and
high-profile ancestry testing companies are all consid-
ering scientific, ethical, and regulatory issues regarding
health-related genetic testing. Now is the time to start
bridging the gap in our current approaches to health
and ancestry genetic testing.
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Additional file
Additional file 1: Examples of associations between mitochondrial DNA
(mtDNA) or Y chromosome variants and diseases/medical traits discussed
in the biomedical literature. Description of data: an extensive list of published
associations between mitochondrial DNA (mtDNA) or Y chromosome variants
and diseases/medical traits. Organised by disease/medical traits, and including:
mtDNA or Y Chromosome Variant; Proposed Association (or Lack of
Association); Study Location; and Reference. (DOCX 58 kb)
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